Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 7
Submit an article Journal homepage
466
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies

Benjamin W. TehDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; ;Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia; Correspondence[email protected]
,
Simon J. HarrisonSir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia; ;Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;
,
Leon J. WorthDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; ;Department of Medicine, University of Melbourne, Victoria, Australia;
&
Monica A. SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; ;Victorian Infectious Diseases Service, Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia
Pages 1719-1722 | Received 27 Aug 2015, Accepted 06 Oct 2015, Published online: 04 Jan 2016

References

  • Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 2014; 28: 75–86.
  • Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107–113.
  • Kamber C, Zimmerli S, Suter-Riniker F, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant 2015; 50: 573–578.
  • Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784–4790.
  • Konig C, Kleber M, Reinhardt H, et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 2014; 93: 479–484.
  • Teh BW, Harrison SJ, Worth LJ, et al. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 2015; 171: 100--108.
  • National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2010.
  • Teh BW, Worth LJ, Harrison SJ, et al. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Support. Care Cancer 2015; 23: 1901–1906.
  • Clave E, Douay C, Coman T, et al. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 2014; 55: 1788–1795.
  • Truong Q, Veltri L, Kanate AS, et al. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol 2014; 93: 677–682.
  • Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071–3077.
  • Teh BW, Slavin MA, Harrison SJ, et al. Prevention of viral infections in patients with multiple myeloma: the role of anti-viral prophylaxis and immunization. Expert Rev Anti Infect Ther 2015; 13: 1325--1336.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.